BPO bioprospect limited

2 year ap778 trial results

  1. 2,753 Posts.
    Described as statistically conclusive in the latest ann. 1.14% AP778 performed significantly better than the solvent and control compounds over 2 years. The company is currently in development agreement discussions with Australian formulation companies.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.